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ABSTRACT: A new synthesis of (+)-brefeldin A is reported
via Padwa allenylsulfone [3 + 2]-cycloadditive elimination.
Cycloadduct 13 was initially elaborated into iodide 27, which,
following treatment with Zn, gave aldehyde 28 whose C(9)
stereocenter was epimerized. Further elaboration into enoate
38 and Julia−Kocienski oleﬁnation with 5 subsequently
aﬀorded 39, which was deprotected at C(1) and O(15).
Yamaguchi macrolactonization of the seco-acid thereafter
aﬀorded a macrocycle that underwent O-desilylation and
inversion at C(4) to give (+)-brefeldin A following
deprotection.
The structurally complex antitumor macrolide, (+)-brefeldinA,1 has occupied an almost iconic position within the ﬁeld
of stereocontrolled natural product total synthesis,2 due to the
signiﬁcant challenges it poses for complex chiral cyclopentane
ring construction. In this connection, and following a recent
successful deployment of the Padwa allenylsulfone anionic [3 +
2]-cycloadditive−elimination3 in the synthesis of (−)-echino-
sporin,4 we became interested in evaluating whether this novel
cyclopentene ring-assembly method might prove useful for the
stereoselective construction of chiral bicyclic cyclopentanoids
with a trans-ring junction, and in this connection, (+)-brefeldin A
immediately sprung to mind as a target.
(+)-Brefeldin A has elicited considerable medicinal interest
over the years,5 due to the fact that its water-soluble 7-N,N-
dimethylglycinate pro-drug, breﬂate, was reported to be a
powerful inhibitor of human melanoma xenograft growth in
mice.6 Despite these early exciting ﬁndings, subsequent more
detailed pharmacological evaluation of breﬂate and other
brefeldin A pro-drugs at higher dosages (20 mg/kg) did
eventually reveal that they could bring about seizures in mice
and cause noticeable neurodegeneration.7 Ultimately, these
observations led to molecules of the brefeldin class not
proceeding into human clinical development. It is now believed
that much of the toxicity of (+)-brefeldin A derives from its
blockade of the interaction between the adenosine diphosphate
ribosylation factor 1 (Arf1)−GDP (guanosine diphosphate)
complex with the Sec7 domains of various Arf−GTPase
exchange factors, which interferes with their normal function-
ing.7−9 Despite these problems, work has continued on the
synthesis of new brefeldin A analogues,5 with many teams
retaining the hope that theymight identify a structurally modiﬁed
congener that will have an improved activity/toxicity proﬁle. It
was with such thoughts in mind, that we too commenced
synthetic eﬀorts on (+)-brefeldin A, and herein, we now report a
new, fully stereocontrolled, enantioselective synthesis.
In our original retrosynthetic plan for (+)-brefeldin A (1)
(Scheme 1), we sought to access 1 from the seco-acid 2 by
regioselective macrolactonization. Compound 2 would emerge
from 3 by cleavage of all the protecting groups, while 3 would
derive from 6 by the successful implementation of E-oleﬁn cross-
metathesis and Julia/Kocienski oleﬁnation10 tactics on 6 and 4,
respectively. Aldehyde 6 would possibly emerge from 8 by
pyrrolidine-induced epimerization, while 8 might be securable
from the pyranoside 9 by Vasella reductive ring cleavage.11
Further retrosynthetic tracing of 9 to 12 suggested compounds
10 and 11 as intermediates, with 11 emerging from a sulfone
carbanion oxidation on 12 and 10 from a ketone reduction. A
double Mitsunobu inversion12 on 10with benzoic acid and an O-
desilylation and iodination would thereafter complete the route
to 9. The requisite Padwa anionic [3 + 2]-cycloadduct 13 had
already been prepared from 16 and 17 during our development
of a new pathway to (−)-echinosporin,4 and so now we
envisioned converting 13 into 12 by a simple catalytic
hydrogenation reaction.
With this summary of our strategy in mind, we repeated the
work of Flasz and Hale4 to acquire cycloadduct 13 in the
previously reported 56% yield (Scheme 2). The alkene in 13 was
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hydrogenated. The cyclopentylsulfone next had its ketone
reduced from its less hindered underside with L-Selectride to
provide alcohol 12 with total stereocontrol. Conversion of 12
into 11 was now attempted by forming the dianion of 12 with 2
equiv of n-BuLi in THF/HMPA at −78 °C and oxidizing this
with the Davis oxaziridine.13 Disappointingly, this reaction failed
to give any of the desired ketone 11 even when attempted under
a range of conditions.
We therefore sought to arrive at iodide 9 by a pathway
(Scheme 3) that set oﬀ from the known (8S)-α-hydroxy ketone
18, preparable from 13.4 On this occasion, we hoped to access 9
from triol 21 by selective iodination and double invertive
Mitsunobu displacement of 25 with PhCO2H,
12 but ﬁrst we
established whether such a double inversion would indeed be
feasible on 21 to obtain 24. Hydroxy ketone 18 was thus
successfully converted into 19 by Barton deoxygenation14 of the
(8S)-O-thiocarbonylimidazolide with Bu3SnH/cat. AIBN in
PhMe at reﬂux for 1 h. With regard to preparation of the O-
thionocarbonylimidazolide, it proved essential not to add DMAP
to the mix; otherwise, the epimeric (8R)-C(8)-O-thionocarbo-
nylimidazolide would start to arise, and this would subsequently
not undergo Barton deoxygenation with Bu3SnH/AIBN! With
19 in hand, L-Selectride reduction gave alcohol 20 as a single
isomer, and O-desilylation led to 21. Despite many attempts, we
were unsuccessful in eﬀecting the desired double Mitsunobu
inversion on 21 to obtain 24.
Instead, only the di-O-benzoate 22 and elimination product 23
were formed in 30 and 14% yield, respectively. This result and
those of other C(4) inversion studies that we performed on
related substrates all conﬁrmed that C(4) inversion would have
to be delayed until the very ﬁnal stages of the synthesis when the
pyranoid ring had been fully dismantled.
Given this setback, we elected to make aldehyde 30 our new
synthetic objective (Scheme 4). Alcohol 20was thus subjected to
Mitsunobu displacement12 to obtain 26; this reaction proceeded
in high yield (81%) and gave a single product. Selective cleavage
of the C(2)−OTBS group from 26 and iodination thereafter
proceeded satisfactorily to deliver iodide 27 in 84% overall yield.
Vasella reductive cleavage11 was next attempted with zinc dust in
aqueous i-PrOH at reﬂux. It proved necessary to follow this
reaction by TLC throughout to ensure that reduction of the
Scheme 1. Our Retrosynthetic Plan for (+)-Brefeldin A
Scheme 2. Our Attempted Synthesis of Ketone 11
Scheme 3. Our Attempted Early Stage Double Mitsunobu
Inversion of Triol 21 at C(4) and C(7)
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aldehyde also did not occur; a 3 h reaction time typically
minimized this event and gave 28 in 95% yield. A variety of bases
were then investigated to perform the desired epimerization of
28 into 29, but pyrrolidine soon emerged as the reagent of
choice, giving a high yield of product with high stereoselectivity.
A fresh disappointment beset us when we discovered that the
alkene in 29 was not a productive partner in oleﬁn cross-
metathesis with excess methyl acrylate to obtain 30 (Scheme 4).
Given this undesired outcome, we decided to investigate whether
a Wittig reaction might prove useful for enoate elaboration, but
clearly, the adoption of this tactic would require reduction of the
C(9)-aldehyde and protection of the resulting alcohol to enable
the C(3)-aldehyde to be oxidatively unveiled. There was also the
issue of C(4) inversion and macrolactonization to contend with
much later in the synthesis. After due consideration, an
orthogonal silyl ether protecting group strategy was eventually
adopted, with aldehyde 29 being converted into diﬀerentially
protected tri-O-silyl ether 33 (Scheme 5).
A four-step protocol accomplished this task (Scheme 5). In
this, NaBH4 reduction of 29 delivered a primary alcohol that
underwent O-silylation with TBSCl and imidazole. Alkene 31
then had its O-benzoate reductively removed with i-Bu2AlH at
low temperature. The resulting alcohol 32 was then O-silylated
with TBDPSCl and imidazole in CH2Cl2 at rt. Initially, the use of
cat. OsO4 and NaIO4 was pursued for the oxidative cleavage of
alkene 33, to obtain 35, but this gave rise to a complex reaction
mixture. In the end, the alkene of 33 was best dihydroxylated
under standard Upjohn conditions with cat. OsO4 and excess N-
methylmorpholine N-oxide.15 This aﬀorded a single diol 34,
whose stereochemistry was tentatively assigned as anti, using
Kishi’s empirical rule.16 This diol was then oxidatively cleaved
with Pb(OAc)4, and the resulting aldehyde 35 Wittig oleﬁnated
to obtain enoate 36 as a single geometric isomer. Selective O-
desilylation of 36 with cat. PPTS/EtOH at rt over 60 h cleanly
gave alcohol 37, which was converted into the aldehyde 38 by
TEMPO/PhI(OAc)2 oxidation. Julia/Kocienski oleﬁnation
10 of
38 with the N-phenyltetrazolylsulfone 5 furnished the all (E)-
alkene 39 as a single stereoisomer in 68% yield. Our new
abridged synthesis of 52e from 4517 is presented in Scheme 6.
Ceric ammonium nitrate cleavage of the PMP group18 from 39
then ensued; the methyl ester was likewise cleaved with aq LiOH.
A Yamaguchi macrolactonization19 of the seco-acid 40 was now
accomplished at high dilution, as described in Scheme 5.
Macrolactone 41was formed in excellent yield, in what was a very
clean reaction. Selective C(4) O-desilylation of 41 could
subsequently be accomplished cleanly and rapidly with 5 equiv
of n-Bu4NF in THF over 1 h. The resulting alcohol was then
subjected to Mitsunobu inversion with Ph3P/DIAD and p-
nitrobenzoic acid.12c The desired product 43was isolated pure in
65% yield; elimination product 42 was also isolated in 17% yield
by SiO2 ﬂash chromatography. With pure 43 in hand,
(+)-brefeldin A was readily accessed after HF-pyridine-induced
Scheme 4. Our Synthesis of the New Alkenyl Aldehyde 29 Scheme 5. Completion of Our Syntheses of (+)-Brefeldin A
(1) and 4-Epi-Brefeldin A (44) from Alkenyl Aldehyde 29
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O-desilylation and brief treatment (0.5 h) with K2CO3 (1 equiv)
in MeOH at 0 °C. Following ﬁnal puriﬁcation by SiO2 ﬂash
chromatography, the natural product was obtained in 70% yield
for the two steps and was spectroscopically identical with the
spectra reported for (+)-brefeldin A in the literature in CD3OD
2f
and CDCl3.
20 Cleavage of the O-silyl protecting groups from 41
with n-Bu4NF in THF aﬀorded 4-epi-brefeldin A,
2h as well.
In summary, a new total synthesis of (+)-brefeldin A was
achieved from the Padwa [3 + 2]-cycloadduct 13. The utility of
the latter cycloaddition was demonstrated for the preparation of
trans-conﬁgured chiral cyclopentanes. New types of brefeldin
analogues should now prove accessible.
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